Compounds > glucose, (beta-d)-isomer
Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Glycosuria

glucose, (beta-d)-isomer has been researched along with Glycosuria in 87 studies

Research

Studies (87)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.15)18.7374
1990's1 (1.15)18.2507
2000's15 (17.24)29.6817
2010's65 (74.71)24.3611
2020's5 (5.75)2.80

Authors

AuthorsStudies
Cao, Y; Chen, X; Chu, C; Delic, D; Frankenreiter, S; Gaballa, MMS; Hasan, AA; Hocher, B; Klein, T; Krämer, BK; Luo, T; Stadermann, K; Xiong, Y; Xue, Y; Yin, L; Zeng, S1
Burchell, R; Burton, SE; Gal, A; Jacob, A; Lopez-Villalobos, N; Malabu, U; Singh, P; Weidgraaf, K1
Chatsudthipong, V; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Swe, MT; Thongnak, L1
Altay, H; Cahn, A; Çavuşoğlu, Y; Celik, A; Demir, S; Kılıçaslan, B; Nalbantgil, S; Raz, I; Temizhan, A; Yıldırımtürk, Ö; Yılmaz, MB1
Arakawa, K; Azumaya, I; Fujikura, H; Fujimori, Y; Fushimi, N; Hikawa, H; Hiratochi, M; Isaji, M; Kamada, N; Katsuno, K; Nakabayashi, T; Nishimura, T; Shimizu, K; Tatani, K; Watanabe, S1
Athan, E; Bartolo, C; Friedman, ND; Fuller, A; Hall, V; Lanyon, C; Morrissey, CO1
Aschemeier, B; Biester, T; Danne, T; Fath, M; Frey, M; Kordonouri, O; Scheerer, MF1
Chung, BH; Jin, J; Jin, L; Lim, SW; Luo, K; Yang, CW1
Amino, N; Hayashizaki, Y; Hirosumi, J; Kurosaki, E; Minoura, H; Takakura, S; Takasu, T1
Glodzik, W; Hohendorff, J; Kapusta, M; Kiec-Wilk, B; Klupa, T; Ludwig-Galezowska, A; Malecki, MT; Mrozinska, S; Parpan, T; Platek, T; Skupien, J; Szopa, M; Zapala, B1
Iuchi, H; Kayama, Y; Matsutani, D; Minamisawa, S; Sakamoto, M; Suzuki, H; Takeda, N; Utsunomiya, K1
Abdul-Ghani, M; Adams, J; Al Jobori, H; Cersosimo, E; Daniele, G; DeFronzo, RA; Solis-Herrera, C; Triplitt, C1
Anzai, N; Batz, F; Breljak, D; Freeman, B; Fu, Y; Huang, W; Koepsell, H; Mayoux, E; Nigam, SK; Onishi, A; Patel, R; Sabolic, I; Song, P; Vallon, V1
George, J; Hanafusa, T; Lee, G; Marquard, J; Sarashina, A; Shiki, K; Shimada, A; Soleymanlou, N; Taneda, Y; Yasui, A1
Forest, CP; Tat, V1
Hitomi, H; Kitabayashi, C; Kobara, H; Kobori, H; Konishi, Y; Li, L; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Zhang, Y1
Aroor, AR; Carpenter, AJ; Chandrasekar, B; Das, NA; DeMarco, VG; Duta, C; Habibi, J; Hayden, MR; Jia, G; Manrique-Acevedo, CM; Martinez-Lemus, L; Mayoux, E; Nistala, R; Padilla, J; Ramirez-Perez, FI1
Kakizaki, S; Kikuchi, O; Kitamura, T; Kobayashi, M; Kohno, D; Matsui, S; Sasaki, T; Suga, T; Takeuchi, K; Wada, E; Yamada, M; Yokota-Hashimoto, H1
Boulton, DW; Parkinson, J; Penland, RC; Sokolov, V; Tang, W; Ueda, S; Yakovleva, T1
Araki, E; Asano, M; Boulton, DW; Kim, H; Shiramoto, M; Tang, W; Thorén, F; Ueda, S; Watada, H; Yajima, T1
Isaka, H; Kaku, K; Sakatani, T; Toyoshima, J1
Hwang, YC; Kim, JH; Lee, BW; Lee, WJ1
Ciaraldi, TP; Farrell, K; Ghosh, A; Henry, RR; Mudaliar, S; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N1
Del Prato, S; Nauck, M1
Ghosh, A; Heise, T; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S1
Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W1
Hinneburg, I1
Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Li, Q; Noda, A; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M1
Boulton, DW; Gould, JC; Kasichayanula, S; Shepperly, DC1
Gerasimova, M; Koepsell, H; Masuda, T; Mayoux, E; Platt, K; Powell, DR; Rieg, T; Thomson, SC; Vallon, V1
Fukazawa, M; Hiramatsu, M; Honda, K; Kawabe, Y; Matsumoto, M; Suzuki, M; Suzuki, Y1
Mauricio, D1
Albarrán, OG; Ampudia-Blasco, FJ1
Baldi, S; Broedl, UC; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Woerle, HJ1
Hayashizaki, Y; Kihara, R; Kurosaki, E; Li, Q; Mitsuoka, K; Miyoshi, S; Muramatsu, Y; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Uchiyama, Y; Yokono, M1
Kumar, M; Kumar, R; Mahapatra, MK; Malla, P1
Gastonguay, MR; Gillespie, W; MacGregor, TR; Macha, S; Riggs, MM; Seman, LJ; Staab, A; Woerle, HJ1
Bogle, A; Chalamandaris, AG; Edelman, S; Griffen, SC; Henry, RR; Iqbal, N; Kasichayanula, S; List, J; Mudaliar, S; Rosenstock, J1
Cherney, DZ; Lytvyn, Y; Perkins, BA; Škrtić, M; Yang, GK; Yip, PM1
Davidson, JA; Kuritzky, L1
Huang, W; Li, Y; Li, Z; Qian, H; Wang, X; Yang, B1
Alba, M; Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Ways, K1
de Bruin, TW; Hamer-Maansson, JE; Parikh, S; Reele, S; Tang, W1
Okada, J; Okada, S; Saito, T; Satoh, T; Shibusawa, R; Shimoda, Y; Tagaya, Y; Yamada, E; Yamada, M1
Cheatham, B; Dobbins, RL; Hussey, EK; Kapur, A; O'Connor-Semmes, R; Tao, W; Walker, S; Wang-Smith, L; Wilkison, WO; Ye, J1
Chen, X; Curtin, CR; Devineni, D; Hu, P; Polidori, D; Sha, S; Stieltjes, H; Vaccaro, N; Weiner, S1
Broedl, UC; Cescutti, J; Eilbracht, J; Famulla, S; Johansen, OE; Kaspers, S; Pieber, TR; Soleymanlou, N; Woerle, HJ1
Broedl, UC; Cui, Y; Lang, B; Macha, S; Pinnetti, S; Salsali, A; Zhao, S; Zhao, X1
Beck, A; Beyer, U; Boerlin, V; Christ, AD; Ciorciaro, C; Cynshi, O; Ikeda, S; Kadowaki, T; Meyer, M; Takano, Y; Tanaka, R1
Boulton, DW; Johnsson, E; LaCreta, F; Leil, TA; Tang, W1
Broedl, UC; Mondick, J; Retlich, S; Riggs, M; Sarashina, A; Sasaki, T1
Edenhofer, I; Kapoor, S; Kipar, A; Mei, C; Riwanto, M; Rodriguez, D; Segerer, S; Wüthrich, RP; Yang, M1
Gilbert, RE; Kepecs, DM; Thai, K; Zhang, Y1
Biagetti, B; Dalama, B; Mesa, J1
Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR1
Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M1
Hoshi, H; Niijima, Y; Okada, S; Ono, K; Osaki, A; Saito, T; Yamada, E; Yamada, M1
Chen, L; Efe, O; Klein, JD; LaRocque, LM; Sands, JM; Wang, J1
Fujikura, H; Fujimori, Y; Isaji, M; Ishikawa-Takemura, Y; Katsuno, K; Nakashima, I1
Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V1
Boulton, D; Geraldes, M; Komoroski, B; Kornhauser, D; Li, L; Pfister, M; Vachharajani, N1
Feng, Y; Komoroski, B; Kornhauser, D; Li, L; Pfister, M; Vachharajani, N1
Bickel, M; Brummerhop, H; Frick, W; Glombik, H; Herling, AW; Heuer, HO; Kramer, W; Plettenburg, O; Theis, S; Werner, U1
Fujimori, Y; Isaji, M; Ishikawa-Takemura, Y; Katsuno, K; Kusama, H; Nakano, S; Nakashima, I; Ojima, K1
Chen, Y; Ding, H; Du, J; Feng, Y; Lv, B; Peng, K; Seed, B; Sheng, Z; Welihinda, A; Xu, B; Xu, G; Zhang, L; Zhang, T; Zhang, W; Zhu, L1
Amin, DM; Clark, RV; Dobbins, RL; Hussey, EK; Kipnes, MS; Layko, D; Leong, J; Murray, SC; Nunez, DJ; O'Connor-Semmes, RL; O'Driscoll, EC1
Dobbins, RL; Hussey, EK; Kapur, A; Layko, D; Murray, SC; Nunez, DJ; O'Connor-Semmes, RL; Stockman, NL; Stoltz, RR1
Forst, T; Hanefeld, M1
Chien, S; Demarest, K; Devineni, D; Ghosh, A; Polidori, D; Rothenberg, P; Sha, S; Shalayda, K; Wexler, D1
Kadokura, T; Krauwinkel, WJ; Smulders, RA; Veltkamp, SA1
Capuano, G; Nicolle, LE; Usiskin, K; Ways, K1
Dugi, KA; Koiwai, K; Negishi, T; Sarashina, A; Seman, LJ; Sesoko, S; Taniguchi, A; Woerle, HJ; Yamamura, N1
Boulton, DW; Humphreys, WG; Kasichayanula, S; LaCreta, FP; Liu, X; Pe Benito, M; Pfister, M; Yao, M1
Fukazawa, M; Honda, K; Ikeda, S; Kato, M; Kawabe, Y; Kawai, M; Mitsui, T; Murao, N; Nagata, T; Suzuki, Y; Yamaguchi, K; Yamane, M; Yata, T1
Forst, T; Rosak, C1
Hantel, S; Heise, T; Macha, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ1
Ferrannini, E; Kadokura, T; Smulders, RA; Veltkamp, SA1
Hatanaka, T; Hirama, R; Ishida, N; Kageyama, Y; Kondo, N; Maezono, K; Matsueda, H; Ohsumi, K; Oonuki, A; Umemura, T1
LEHONGRE, G; NEUMANN, J1
Gregersen, S; Hermansen, K; Holst, JJ; Jeppesen, PB1
Fujikura, H; Fujimori, Y; Hiratochi, M; Isaji, M; Itoh, F; Katsuno, K; Komatsu, Y; Takemura, Y1
Arakawa, K; Funami, N; Hongu, M; Matsumoto, M; Saito, K; Tanaka, T; Tsujihara, K1
Anai, M; Arakawa, K; Asano, T; Kano-Ishihara, T; Matsumoto, M; Nawano, M; Oku, A; Saito, A; Tsujihara, K; Ueta, K1
Prasad, K1
Adachi, T; Iwakura, I; Kitamura, K; Okamoto, Y; Oku, A; Saito, A; Seino, Y; Shihara, N; Tsuda, K; Ueta, K; Yamada, Y; Yano, H; Yasuda, K1
Adachi, T; Arakawa, K; Kano-Ishihara, T; Matsumoto, M; Oku, A; Saito, A; Tsuda, K; Ueta, K; Yasuda, K1
Arakawa, K; Ishihara, T; Kitamura, K; Matsumoto, M; Nawano, M; Oku, A; Saito, A; Ueta, K1

Reviews

9 review(s) available for glucose, (beta-d)-isomer and Glycosuria

ArticleYear
The role of SGLT2 inhibitors in managing type 2 diabetes.
    JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:6

    Topics: Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
[Dapagliflozin. Lowering blood glucose levels by increasing glucosuria].
    Medizinische Monatsschrift fur Pharmazeuten, 2013, Volume: 36, Issue:4

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Drug Interactions; Glucosides; Glycosuria; Humans; Hypoglycemic Agents

2013
[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
    Medicina clinica, 2013, Volume: 141 Suppl 2

    Topics: Adsorption; Animals; Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drugs, Investigational; Glucose; Glucosides; Glycosides; Glycosuria; Glycosuria, Renal; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Malus; Phlorhizin; Phytotherapy; Plant Bark; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome

2013
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
    Medicina clinica, 2013, Volume: 141 Suppl 2

    Topics: Benzhydryl Compounds; Biological Transport, Active; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss

2013
Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.
    Medicinal research reviews, 2014, Volume: 34, Issue:6

    Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Glycemic Index; Glycosuria; Humans; Hypoglycemic Agents; Male; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome

2014
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Homeostasis; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2014
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents

2016
Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3

    Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Models, Statistical; Randomized Controlled Trials as Topic; Renal Reabsorption

2016
[Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
    MMW Fortschritte der Medizin, 2012, Dec-17, Volume: 154 Suppl 4

    Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Glipizide; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2012

Trials

32 trial(s) available for glucose, (beta-d)-isomer and Glycosuria

ArticleYear
The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
    Domestic animal endocrinology, 2020, Volume: 70

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cats; Cross-Over Studies; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Male; Sodium-Glucose Transporter 2 Inhibitors

2020
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:11

    Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Benzhydryl Compounds; Child; Cross-Over Studies; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Male; Pilot Projects; Young Adult

2017
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.
    The Journal of clinical endocrinology and metabolism, 2018, 04-01, Volume: 103, Issue:4

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged

2018
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:9

    Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult

2018
Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glucuronides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors

2019
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:6

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult

2019
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
    Diabetes care, 2013, Volume: 36, Issue:8

    Topics: Acetaminophen; Adolescent; Adult; Blood Glucose; Canagliflozin; Cross-Over Studies; Depression, Chemical; Gastric Emptying; Glucose; Glucosides; Glycosuria; Humans; Insulin; Intestinal Absorption; Male; Placebos; Postprandial Period; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2013
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:5

    Topics: Blood Glucose; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Male; Membrane Transport Modulators; Middle Aged; Overweight; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2013
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
    BMC pharmacology & toxicology, 2013, Apr-30, Volume: 14

    Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2013
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.
    Regulatory toxicology and pharmacology : RTP, 2013, Volume: 67, Issue:1

    Topics: Benzhydryl Compounds; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Kidney; Male; Occupational Exposure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2013
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:2

    Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Oxygen; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2014
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult

2015
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Insulin; Male; Middle Aged; Mycoses; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections; Weight Loss

2015
Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Drug Administration Schedule; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney; Middle Aged; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Young Adult

2015
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
    Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:7

    Topics: Adult; Aged; Area Under Curve; Female; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2015
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
    Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7

    Topics: Adolescent; Adult; Asian People; Blood Glucose; Canagliflozin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Healthy Volunteers; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult

2015
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10

    Topics: Adult; Austria; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss

2015
Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
    Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7

    Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors

2015
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10

    Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Fasting; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Ketones; Male; Metformin; Middle Aged

2015
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
    Diabetes, 2016, Volume: 65, Issue:5

    Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors

2016
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
    Diabetes care, 2009, Volume: 32, Issue:4

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sodium-Glucose Transport Proteins; Weight Loss; Young Adult

2009
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
    Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:5

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors

2009
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
    Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:5

    Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose Tolerance Test; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors

2009
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucose; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Prodrugs; Water-Electrolyte Balance

2010
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:6

    Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Glycosuria; Half-Life; Humans; Insulin; Male; Middle Aged; Obesity; Overweight; Prodrugs; Water-Electrolyte Balance

2010
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult

2011
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
    Clinical drug investigation, 2011, Dec-01, Volume: 31, Issue:12

    Topics: Adult; Blood Glucose; Blood Pressure Determination; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Glucose; Glucosides; Glycosuria; Heart Rate; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiophenes; Young Adult

2011
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Current medical research and opinion, 2012, Volume: 28, Issue:7

    Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections

2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
    Drug metabolism and pharmacokinetics, 2013, Volume: 28, Issue:3

    Topics: Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Glucosides; Glycosuria; Half-Life; Humans; Male; Metabolic Clearance Rate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2013
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    British journal of clinical pharmacology, 2013, Volume: 76, Issue:3

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney; Kidney Function Tests; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult

2013
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:7

    Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Germany; Glucosides; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Male; Membrane Transport Modulators; Middle Aged; Polyuria; Sodium-Glucose Transporter 2 Inhibitors

2013
Antihyperglycemic effects of stevioside in type 2 diabetic subjects.
    Metabolism: clinical and experimental, 2004, Volume: 53, Issue:1

    Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Diuresis; Fatty Acids, Nonesterified; Female; Food; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged; Peptide Fragments; Placebos; Protein Precursors; Triglycerides

2004

Other Studies

46 other study(ies) available for glucose, (beta-d)-isomer and Glycosuria

ArticleYear
Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 146

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Dose-Response Relationship, Drug; Fibrosis; Glucosides; Glycosuria; Heart Diseases; Iron; Kidney Diseases; Male; Nephrectomy; Rats; Rats, Wistar; Sequence Analysis, RNA; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Telmisartan

2022
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Clinical science (London, England : 1979), 2019, 12-12, Volume: 133, Issue:23

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Endoplasmic Reticulum Stress; Gluconeogenesis; Glucosides; Glycosuria; Insulin Resistance; Liver; Male; Metformin; Obesity; Pancreas; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors

2019
[Sodium glucose co-transporter 2 inhibitors in heart failure therapy].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2020, Volume: 48, Issue:3

    Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diastole; Diuresis; Female; Glucosides; Glycosuria; Heart Failure; Heart Ventricles; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Myocardium; Natriuresis; Physical Endurance; Quality of Life; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Walk Test

2020
Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
    Bioorganic & medicinal chemistry, 2021, 03-15, Volume: 34

    Topics: Administration, Oral; Animals; Biological Availability; Chlorocebus aethiops; COS Cells; Drug Discovery; Glucosides; Glycosuria; Mice; Molecular Structure; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2021
Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports.
    BMC infectious diseases, 2021, Mar-20, Volume: 21, Issue:1

    Topics: Aged; Benzhydryl Compounds; Candidiasis; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Pharmaceutical Preparations; Sodium-Glucose Transporter 2 Inhibitors

2021
Effect of Empagliflozin on Tacrolimus-Induced Pancreas Islet Dysfunction and Renal Injury.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017, Volume: 17, Issue:10

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Kidney; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sodium-Glucose Transporter 2; Tacrolimus

2017
The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:5

    Topics: Absorptiometry, Photon; Adipose Tissue; Animals; Body Composition; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss

2017
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Endocrine, 2017, Volume: 57, Issue:2

    Topics: Adult; Aged; Benzhydryl Compounds; Creatinine; Deoxyglucose; Diabetes Mellitus, Type 2; Female; Glucokinase; Glucosides; Glycosuria; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Male; Middle Aged; Mutation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult

2017
Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
    Scientific reports, 2017, 09-19, Volume: 7, Issue:1

    Topics: Animals; Blood Glucose; Body Temperature; Circadian Rhythm; Diabetes Mellitus, Type 2; Drinking; Eating; Energy Metabolism; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2017
Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    American journal of physiology. Renal physiology, 2018, 08-01, Volume: 315, Issue:2

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Glomerular Filtration Rate; Glucosides; Glycosuria; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Mice, Knockout; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2018
Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats.
    Journal of pharmacological sciences, 2018, Volume: 137, Issue:2

    Topics: Administration, Oral; Angiotensin II; Angiotensinogen; Animals; Disease Models, Animal; Glucosides; Glycosuria; Indoles; Kidney; Male; Nephrectomy; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2018
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Cardiovascular diabetology, 2018, 07-30, Volume: 17, Issue:1

    Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Endothelium, Vascular; Female; Glucosides; Glycosuria; GPI-Linked Proteins; Humans; Kidney; Mice, Inbred C57BL; Mice, Mutant Strains; Pulsatile Flow; Renal Circulation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Vascular Stiffness; Vasodilation

2018
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Molecular metabolism, 2019, Volume: 19

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2019
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors; United States; Young Adult

2019
A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
    Diabetes & metabolism journal, 2019, Volume: 43, Issue:6

    Topics: Adult; Aged; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Republic of Korea; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult

2019
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds

2013
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    European journal of pharmacology, 2013, Sep-05, Volume: 715, Issue:1-3

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Tolerance Test; Glucosides; Glycosuria; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Male; Mice; Obesity; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2013
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
    American journal of physiology. Renal physiology, 2014, Volume: 306, Issue:2

    Topics: Animals; Benzhydryl Compounds; Biological Transport, Active; Blood Glucose; Dose-Response Relationship, Drug; Drinking; Eating; Female; Glucose; Glucosides; Glycosuria; Kidney; Kidney Tubules, Proximal; Male; Mice; Mice, Knockout; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urodynamics

2014
Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:7

    Topics: Animals; Benzhydryl Compounds; Canagliflozin; Candida albicans; Candidiasis; Disease Progression; Female; Glucosides; Glycosuria; Kidney; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections

2014
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
    European journal of pharmacology, 2014, Mar-15, Volume: 727

    Topics: Adiposity; Animals; Anti-Obesity Agents; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Fatty Acids; Glucosides; Glycosuria; Hypoglycemic Agents; Lipid Metabolism; Obesity; Oxidation-Reduction; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Up-Regulation; Weight Loss

2014
Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
    British journal of clinical pharmacology, 2014, Volume: 78, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Biological; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors

2014
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus.
    American journal of physiology. Renal physiology, 2015, Jan-15, Volume: 308, Issue:2

    Topics: Adult; Benzhydryl Compounds; Case-Control Studies; Diabetes Mellitus, Type 1; Female; Glucosides; Glycosuria; Humans; Hyperglycemia; Male; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid; Young Adult

2015
C-Aryl Glucosides with Substituents at the Distal Aryl Ring as Sodium-Dependent Glucose Cotransporter Inhibitors for the Treatment of Diabetes Mellitus.
    Chemical biology & drug design, 2015, Volume: 86, Issue:2

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice; Random Allocation; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transport Proteins; Structure-Activity Relationship

2015
Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report.
    Journal of medical case reports, 2014, Dec-16, Volume: 8

    Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Drug Therapy, Combination; Glucosides; Glycosuria; Humans; Male; Middle Aged; Nifedipine; Tetrazoles; Thiophenes; Treatment Outcome

2014
Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
    Kidney & blood pressure research, 2015, Volume: 40, Issue:6

    Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Urea Nitrogen; Diuresis; Female; Glucosides; Glycosuria; Kidney; Kidney Function Tests; Male; Organ Size; Polycystic Kidney Diseases; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urodynamics

2015
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Disease Progression; Fibrosis; Gene Expression; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Male; Nephrectomy; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Treatment Failure

2016
[Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
    Medicina clinica, 2016, May-20, Volume: 146, Issue:10

    Topics: Benzhydryl Compounds; Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Journal of pharmacological sciences, 2016, Volume: 130, Issue:3

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution

2016
Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy.
    Journal of diabetes investigation, 2016, Volume: 7, Issue:5

    Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome

2016
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.
    The American journal of the medical sciences, 2016, Volume: 352, Issue:5

    Topics: Animals; Aquaporin 2; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucosides; Glycosuria; Kidney; Male; Membrane Transport Proteins; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Solute Carrier Family 12, Member 1; Urea Transporters; Water-Electrolyte Balance

2016
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 327, Issue:1

    Topics: Animals; Chlorocebus aethiops; COS Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glucose Tolerance Test; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2008
Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats.
    Arzneimittel-Forschung, 2008, Volume: 58, Issue:11

    Topics: Animals; Blood Glucose; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Glucose; Glucose Tolerance Test; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Kidney; Mice; Phlorhizin; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2008
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
    European journal of pharmacology, 2009, May-01, Volume: 609, Issue:1-3

    Topics: Animals; Area Under Curve; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fasting; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Glycosuria; Hypoglycemic Agents; Insulin; Kinetics; Male; Rats; Rats, Zucker; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin

2009
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, Dec-15, Volume: 19, Issue:24

    Topics: Animals; Benzofurans; Blood Glucose; Glucosides; Glycosuria; Humans; Pyrans; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Spiro Compounds

2009
Dapagliflozin, an SGLT2 inhibitor, for diabetes.
    Lancet (London, England), 2010, Jun-26, Volume: 375, Issue:9733

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors

2010
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    American journal of physiology. Endocrinology and metabolism, 2013, Feb-15, Volume: 304, Issue:4

    Topics: Absorption; Animals; Benzhydryl Compounds; Blood Glucose; Creatinine; Dose-Response Relationship, Drug; Gluconeogenesis; Glucosides; Glycosuria; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Phlorhizin; Rats; Rats, Wistar; Sodium Channel Blockers; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2013
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
    Diabetes care, 2013, Volume: 36, Issue:5

    Topics: Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2013
Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors.
    Bioorganic & medicinal chemistry letters, 2003, Jul-21, Volume: 13, Issue:14

    Topics: Animals; Enzyme Inhibitors; Glucose; Glucosides; Glycosuria; Hypoglycemic Agents; Indicators and Reagents; Injections, Intravenous; Kidney; Membrane Glycoproteins; Microvilli; Monosaccharide Transport Proteins; Pyrazoles; Rats; Rats, Wistar; Sodium-Glucose Transporter 1; Structure-Activity Relationship

2003
[On the glycosuric activity of phlorizoside, of phloretol and of 1,3,4,5-tetrahydroxybenzene 5-glucoside (hydroxyphlorizoside-1)].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1960, Volume: 154

    Topics: Benzene Derivatives; Glucosides; Glycosuria; Phenols; Phlorhizin; Propiophenones

1960
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 320, Issue:1

    Topics: Absorption; Animals; Blood Glucose; Dogs; Electrolytes; Erythrocytes; Female; Glucose; Glucose Tolerance Test; Glucosides; Glycosuria; Hypoglycemic Agents; Kidney; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2007
Na(+)-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4'-dehydroxyphlorizin derivatives.
    Chemical & pharmaceutical bulletin, 1998, Volume: 46, Issue:1

    Topics: Animals; Blood Glucose; Glucose; Glucosides; Glycosuria; Hypoglycemic Agents; Kidney; Male; Membrane Glycoproteins; Monosaccharide Transport Proteins; Phlorhizin; Rats; Rats, Sprague-Dawley; Sodium; Sodium-Glucose Transporter 1; Structure-Activity Relationship

1998
Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats.
    European journal of pharmacology, 2000, Mar-10, Volume: 391, Issue:1-2

    Topics: Animals; Animals, Newborn; Blood Glucose; Carbonates; Diabetes Mellitus, Experimental; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Glucose Transporter Type 1; Glucose Transporter Type 4; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Microvilli; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Sodium

2000
Oxidative stress as a mechanism of diabetes in diabetic BB prone rats: effect of secoisolariciresinol diglucoside (SDG).
    Molecular and cellular biochemistry, 2000, Volume: 209, Issue:1-2

    Topics: Animals; Butylene Glycols; Diabetes Mellitus, Type 1; Glucosides; Glycosuria; Humans; Hyperglycemia; Lipid Peroxidation; Malondialdehyde; Oxidative Stress; Pancreas; Rats; Rats, Inbred BB; Reactive Oxygen Species

2000
T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.
    Metabolism: clinical and experimental, 2000, Volume: 49, Issue:8

    Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Carbonates; Diabetes Mellitus, Experimental; Glucose Transporter Type 2; Glucosides; Glycated Hemoglobin; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Jejunum; Kidney; Male; Monosaccharide Transport Proteins; Organ Size; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Urine

2000
Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats.
    Biological & pharmaceutical bulletin, 2000, Volume: 23, Issue:12

    Topics: Animals; Blood Glucose; Carbonates; Diabetes Mellitus, Experimental; Glucosides; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney; Male; Microvilli; Monosaccharide Transport Proteins; Rats; Rats, Sprague-Dawley; Rats, Wistar

2000
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
    British journal of pharmacology, 2001, Volume: 132, Issue:2

    Topics: Animals; Blood Glucose; Carbonates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon; Glucose Tolerance Test; Glucosides; Glycosuria; Hypoglycemic Agents; Insulin; Kidney Glomerulus; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Obese; Microvilli; Monosaccharide Transport Proteins; Pancreas; Phenotype; Sodium-Glucose Transporter 1

2001
chemdatabank.com